|
1
|
Maeyama I: Review of bone tumor. Iryo.
24:(Suppl):. S2271970.(In Japanese).
|
|
2
|
Sanchez-Pareja A, Larousserie F,
Boudabbous S, Beaulieu JY, Mach N, Saiji E and Rougemont AL: Giant
cell tumor of bone with pseudosarcomatous changes leading to
premature denosumab therapy interruption: A case report with review
of the literature. Int J Surg Pathol. 24:366–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang L, Garcia-Manero G, Jabbour E,
Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL and Wang SA:
Persistence of immunophenotypically aberrant CD34+ myeloid
progenitors is frequent in bone marrow of patients with
myelodysplastic syndromes and myelodysplastic/myeloproliferative
neoplasms treated with hypomethylating agents. J Clin Pathol.
pii:jclinpath-2016-203715. 2016.
|
|
4
|
Sever C, Abbott CL, de Baca ME, Khoury JD,
Perkins SL, Reichard KK, Taylor A, Terebelo HR, Colasacco C, Rumble
RB and Thomas NE: Bone marrow synoptic reporting for hematologic
neoplasms: Guideline from the college of American pathologists
pathology and laboratory quality center. Arch Pathol Lab Med.
140:932–949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lekovic D, Gotic M, Skoda R,
Beleslin-Cokic B, Milic N, Mitrovic-Ajtic O, Nienhold R, Sefer D,
Suboticki T and Buac M: et alBone marrow microvessel density
and plasma angiogenic factors in myeloproliferative neoplasms:
Clinicopathological and molecular correlations. Ann Hematol.
96:393–404. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song T, Zhang X, Fang M, Zhao R and Wu S:
Long-term results of definitive concurrent chemoradiotherapy using
paclitaxel plus oxaliplatin in unresectable locally advanced
esophageal cancer: A prospective phase II trial. Cancer Med.
5:3371–3377. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukuchi M, Mochiki E, Ishiguro T, Ogura T,
Sobajima J, Kumagai Y, Ishibashi K and Ishida H: Efficacy of
Nab-Paclitaxel as second-line chemotherapy for unresectable or
recurrent gastric cancer. Anticancer Res. 36:6699–6703. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garon EB, Neidhart JD, Gabrail NY, de
Oliveira MR, Balkissoon J and Kabbinavar F: A randomized Phase II
trial of the tumor vascular disrupting agent CA4P (fosbretabulin
tromethamine) with carboplatin, paclitaxel, and bevacizumab in
advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther.
9:7275–7283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kreger BT, Johansen ER, Cerione RA and
Antonyak MA: The enrichment of survivin in exosomes from breast
cancer cells treated with paclitaxel promotes cell survival and
chemoresistance. Cancers. 8(pii): E1112016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Gao Y, Shen J, Yang W, Choy E,
Mankin H, Hornicek FJ and Duan Z: Cyclin-dependent kinase 11
(CDK11) is required for ovarian cancer cell growth in vitro and in
vivo, and its inhibition causes apoptosis and sensitizes cells to
paclitaxel. Mol Cancer Ther. 15:1691–1701. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Awasthi N, Scire E, Monahan S, Grojean M,
Zhang E, Schwarz MA and Schwarz RE: Augmentation of response to
nab-paclitaxel by inhibition of insulin-like growth factor (IGF)
signaling in preclinical pancreatic cancer models. Oncotarget.
7:46988–47001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Li D, Li X, Ou X, Liu S, Zhang Y,
Ding J and Xie B: Mammalian target of rapamycin inhibitor RAD001
sensitizes endometrial cancer cells to paclitaxel-induced apoptosis
via the induction of autophagy. Oncol Lett. 12:5029–5035. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Şakalar Ç, İzgi K, İskender B, Sezen S,
Aksu H, Çakır M, Kurt B, Turan A and Canatan H: The combination of
thymoquinone and paclitaxel shows anti-tumor activity through the
interplay with apoptosis network in triple-negative breast cancer.
Tumour Biol. 37:4467–4477. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Peng XX, Sun R, Li J, Zhan XR, Wu
LJ, Wang SL and Xie T: Systematic review of β-elemene injection as
adjunctive treatment for lung cancer. Chin J Integr Med.
18:813–823. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang
J, Qu X and Liu Y: β-Elemene-induced autophagy protects human
gastric cancer cells from undergoing apoptosis. BMC Cancer.
11:1832011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li QQ, Wang G, Huang F, Banda M and Reed
E: Antineoplastic effect of beta-elemene on prostate cancer cells
and other types of solid tumour cells. J Pharm Pharmacol.
62:1018–1027. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oberhaus SM: TUNEL and immunofluorescence
double-labeling assay for apoptotic cells with specific antigen(s).
Methods Mol Biol. 218:85–96. 2003.PubMed/NCBI
|
|
18
|
Li YF, Cha TL, Jin JS and Yu CP:
Chromophobe renal cell carcinoma with osteosarcoma differentiation:
Case report and literature review. Urol Int. 85:470–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kager L, Pötschger U and Bielack S: Review
of mifamurtide in the treatment of patients with osteosarcoma. Ther
Clin Risk Manag. 6:279–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Uehara H, Yazici S, Langley RR, He
J, Tsan R, Fan D, Killion JJ and Fidler IJ: Simultaneous blockade
of platelet-derived growth factor-receptor and epidermal growth
factor-receptor signaling and systemic administration of paclitaxel
as therapy for human prostate cancer metastasis in bone of nude
mice. Cancer Res. 64:4201–4208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang G, Li X, Huang F, Zhao J, Ding H,
Cunningham C, Coad JE, Flynn DC, Reed E and Li QQ: Antitumor effect
of beta-elemene in non-small-cell lung cancer cells is mediated via
induction of cell cycle arrest and apoptotic cell death. Cell Mol
Life Sci. 62:881–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li QQ, Wang G, Reed E, Huang L and Cuff
CF: Evaluation of cisplatin in combination with β-elemene as a
regimen for prostate cancer chemotherapy. Basic Clin Pharmacol
Toxicol. 107:868–876. 2010.PubMed/NCBI
|
|
23
|
Liu J, Hu XJ, Jin B, Qu XJ, Hou KZ and Liu
YP: β-Elemene induces apoptosis as well as protective autophagy in
human non-small-cell lung cancer A549 cells. J Pharm Pharmacol.
64:146–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Li Y, Zhang Y, Song J, Wang Q,
Zheng L and Liu D: Beta-elemene blocks epithelial-mesenchymal
transition in human breast cancer cell line MCF-7 through
Smad3-mediated down-regulation of nuclear transcription factors.
PLoS One. 8:e587192013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Cho SG, Wu X, Siwko S and Liu M:
G-protein coupled receptor 124 (GPR124) in endothelial cells
regulates vascular endothelial growth factor (VEGF)-induced tumor
angiogenesis. Curr Mol Med. 14:543–554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Airley R: Lab reports and cat scans: Can
veterinary oncology guide our way to new treatments for human
cancers? Future Med Chem. 4:1391–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding D and Kong WM: Analysis of relative
factors of bone marrow suppression after chemotherapy with
carboplatin and paclitaxel on the patients with ovarian cancer.
Zhonghua fu chan ke za zhi. 46:188–192. 2011.(In Chinese).
PubMed/NCBI
|
|
28
|
Miller K, Eldar-Boock A, Polyak D, Segal
E, Benayoun L, Shaked Y and Satchi-Fainaro R: Antiangiogenic
antitumor activity of HPMA copolymer-paclitaxel-alendronate
conjugate on breast cancer bone metastasis mouse model. Mol Pharm.
8:1052–1062. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen JR, Jia XH, Wang H, Yi YJ, Wang JY
and Li YJ: Timosaponin A-III reverses multi-drug resistance in
human chronic myelogenous leukemia K562/ADM cells via
downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt
signaling pathway. Int J Oncol. 48:2063–2070. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kurata M, Hasegawa M, Nakagawa Y, Abe S,
Yamamoto K, Suzuki K and Kitagawa M: Expression dynamics of drug
resistance genes, multidrug resistance 1 (MDR1) and lung resistance
protein (LRP) during the evolution of overt leukemia in
myelodysplastic syndromes. Exp Mol Pathol. 81:249–254. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ijichi K, Adachi M, Ogawa T, Hasegawa Y
and Murakami S: Cell-cycle distribution and Thymidilate Synthatase
(TS) expression correlate with 5-FU resistance in head and neck
carcinoma cells. Anticancer Res. 34:2907–2911. 2014.PubMed/NCBI
|
